Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 21,521

Document Document Title
WO/2016/135262A1
The invention relates to the field of medicine and particularly to the use of amino-C2-C6-alkyl nitrates or amino-C2-C4-alkyl nitrates or the pharmaceutically acceptable salt thereof for the treatment and prophylaxis of a chronic disease...  
WO/2016/137963A1
Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include a...  
WO/2016/136933A1
A pharmaceutical composition for treating IL-6-related diseases having as an active ingredient an IL-6 inhibitor, wherein the pharmaceutical composition is administered as usual after a short-interval dosing period where the same dose as...  
WO/2016/135644A1
The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.  
WO/2016/133838A1
Disclosed are 2,2'-bipyridyl compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvat...  
WO/2016/128358A1
Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (ALS) by inhibiting IgG-mediated activation of voltage-gated calcium channels (VGCCs) in cells of the subject, by one or more of...  
WO/2016/128772A1
The present invention relates to BKCa activators for use in the treatment of a muscular disorder, or for controlling spasticity or tremors, for example, spasticity in MS.  
WO/2016/129140A1
An intraoral rapid disintegration tablet that comprises fine grains, said fine grains having, at the center, a drug substance-containing core containing butylscopolamine bromide and water-insoluble particles and being provided with an in...  
WO/2016/124922A1
A composition comprising CRH, CRH binding protein (CRH-BP), alpha-2 macroglobulin (A2M) and alpha-melanocyte stimulating hormone (alpha-MSH) for use in treatment of a medical condition selected from the list consisting of an ulcer or sof...  
WO/2016/127135A1
Disclosed herein are compounds that are effective for treatment of various disease states. Dosing includes both single administration and regimens of cycling dosages.  
WO/2016/125025A1
A composition for improving muscle metabolism in a subject and methods for manufacturing and using same. Embodiments include compositions having an extract of Rhaponticum and an extract of Rhodiola. An extract of Rhaponticum may include ...  
WO/2016/121923A1
The present invention pertains to a muscle synthesis promoter which exhibits a muscle synthesis promotion action, and with which it is possible to efficiently ingest milk protein. More specifically, the present invention pertains to a mu...  
WO/2016/120647A3
PPARγ controls the expression of the TGFβ family member, GDF3, which in turn regulates the restoration of skeletal muscle integrity by promoting muscle progenitor cell differentiation. Thus, GDF3 as a secreted extrinsic effector protei...  
WO/2016/120647A4
PPARγ controls the expression of the TGFβ family member, GDF3, which in turn regulates the restoration of skeletal muscle integrity by promoting muscle progenitor cell differentiation. Thus, GDF3 as a secreted extrinsic effector protei...  
WO/2016/120652A1
PPARγ controls the expression of the TGFβ family member, GDF3, which in turn regulates the restoration of skeletal muscle integrity by promoting muscle progenitor cell differentiation. Thus, GDF3 as a secreted extrinsic effector protei...  
WO/2016/114322A1
The present invention provides an agent for the prevention and/or treatment of amyotrophic lateral sclerosis (ALS), the agent containing: one or more kinase inhibitors selected from the group consisting of epidermal growth factor recepto...  
WO/2016/112497A1
Provided are a human anti-human interferon alpha (IFNα) antibody and coding gene and application thereof. By combining a gene engineering method with a bacteriophage surface display technology, a plurality of subtype anti-human IFNα ge...  
WO/2016/111347A1
Provided is a drug the active ingredient of which is a compound having antagonistic activity against EP4 receptor in the prevention and/or treatment of disease attributed to activation of EP4 receptor. The compound represented by general...  
WO/2016/111357A1
The present invention is directed to the compound (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9- tetrahydrospiro[ß-carboline-4,1'-cyclopropane] represented by the formula. This compound, when compared to conventionally-kno...  
WO/2016/108288A1
A method for producing skeletal muscle progenitor cells from pluripotent stem cells, said method comprising the following steps (1) and (2A) or (2B):(1) a step for culturing the pluripotent stem cells in a liquid culture medium containin...  
WO/2016/106626A1
A Bruton's Tyrosine Kinase (Btk) inhibitor compounds of Formula (I), or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use of Btk inhibito...  
WO/2016/106625A1
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use ...  
WO/2016/098061A1
Described herein are methods of treating and preventing muscle wasting and muscle loss, using adherent stromal cells and conditioned medium produced thereby.  
WO/2016/097299A1
Compound for treatment of myotonic dystrophy type The present invention relates to a compound, or a salt thereof, and a pharmaceutical composition comprising said compound, or a salt thereof, for use in the prevention and/or treatment of...  
WO/2016/092439A1
The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age- related sarcopenia. Especially, the myostatin or activin antagon...  
WO/2016/092139A1
The invention relates to a drug that permits the effective treatment of motor neurone diseases. In particular, the invention relates to a composition comprising a) a compound or any of the pharmaceutically acceptable salts thereof, where...  
WO/2016/088797A1
Provided are: a nucleic acid that reduces toxicity caused by abnormal accumulation of an RNA-binding protein in cells and is usable for preventing or treating a neurodegenerative disease; and a prophylactic or therapeutic agent for a neu...  
WO/2016/089304A1
The present invention provides a method of treating one or more sodium channel related diseases or disorders in an individual, including related symptoms. The method comprises administering to the individual a tetrahydropyridine derivati...  
WO/2016/086103A1
The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibros...  
WO/2016/086114A1
The present invention relates to methods and sports drink compositions for treating and/or preventing muscle weakness and/or increasing muscle strength and/or stamina in subjects in need thereof. The sports drink composition includes meg...  
WO/2016/086136A1
The invention relates to fatty acid cysteamine conjugates of a CFTR modulator, compositions comprising a fatty acid cysteamine conjugate of a CFTR modulator, and methods for using such conjugates and compositions to treat disease, such a...  
WO/2016/084816A1
Provided is a bicyclic compound having an inhibitory effect on acetyl-CoA carboxylase. A compound represented by the formula: (in the formula, each of the symbols is as defined in the specification) or a salt thereof has an inhibitory ef...  
WO/2016/084870A1
Provided is an acylaminophenyl-group-containing compound having a neuroprotective effect. Also provided is a neuroprotective agent including an acylaminophenyl-group-containing compound. A novel acylaminophenyl-group-containing compound,...  
WO/2016/084412A1
It is found that the activation of a B cell can be inhibited by TGF-beta3 produced by LAG3+ Treg. A B cell activation inhibitor comprising TGF-beta3 or a molecule having the function of TGF-beta3 and a therapeutic agent for autoimmune di...  
WO/2016/080887A1
The present invention relates to FHLl (Four-and-a-half-LIM domain 1) as a new muscle specific autoantigen. The invention provides methods for diagnosis of autoimmune muscle diseases, such as myositis, polymyositis, deimatomyositis, inclu...  
WO/2016/080516A1
The present invention provides a pharmaceutical composition containing cilnidipine or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention relates to: a dynamin-related protein 1 (Drp1) polymerization...  
WO/2016/075137A1
The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of s...  
WO/2016/075285A1
The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the ...  
WO/2016/075288A1
The present invention relates to caffeine for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising caffeine for use in the treatment of myotonic dystrophy type 1 and ...  
WO/2016/076434A1
Disclosed are a muscular dystrophy therapeutic agent using pluripotent stem cells obtained from dental pulp, and a method for producing the same. This muscular dystrophy therapeutic agent contains, as an active ingredient, cells derived ...  
WO/2016/073545A1
This invention relates to novel phenyloxadiazole benzoic acids, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods ...  
WO/2016/063933A1
Provided is a heterocyclic compound that has an excellent RBP4 reducing effect and is useful as a preventive or therapeutic drug for diseases or symptoms mediated by a rise in RBP4 or by retinol supplied by RBP4. A compound represented b...  
WO/2016/061632A1
The present invention provides an isolated or recombinant Fn14-binding protein comprising an antigen binding domain, wherein the antigen binding domain binds specifically to Fn14 or a cell expressing Fn14.  
WO/2016/059411A1
The present invention relates to the use of cannabinoids in the treatment of degenerative skeletal muscle disease. In particular the degenerative skeletal muscle disease is Duchenne muscular dystrophy (DMD). Preferably the cannabinoids a...  
WO/2016/059287A1
The present invention relates to a method of treating motor neuron diseases such as amyotrophic lateral sclerosis (ALS) using levosimendan or its active metabolite (II) as an active ingredient. Levosimendan or its active metabolite (II) ...  
WO/2016/056645A1
In the present invention, an expression vector that promotes lysosome uptake of a target nucleic acid and identifies a protein that induces degradation of an abnormal nucleic acid, or includes the genes encoding the same, has been develo...  
WO/2016/057322A1
Provided herein are deuterated compounds and compositions useful in increasing PPAR5 activity. The compounds and compositions provided herein are useful for the treatment of PPAR5 related diseases (e.g., muscular diseases, vascular disea...  
WO/2016/057656A1
Provided herein are methods for increasing PPAR5 activity and methods for treating PPARδ related diseases (e.g., mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases, and metabolic diseases).  
WO/2016/054742A1
Disclosed are apparatus and methods for producing and delivering vapour medicament. An exemplary apparatus disclosed comprises: a gas inlet for receiving a gas from a source of pressurized gas; a chamber for receiving a liquid medicament...  
WO/2016/057658A8
Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular d...  

Matches 101 - 150 out of 21,521